1. Home
  2. JRI vs HUMA Comparison

JRI vs HUMA Comparison

Compare JRI & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Real Asset Income and Growth Fund of Beneficial Interest

JRI

Nuveen Real Asset Income and Growth Fund of Beneficial Interest

HOLD

Current Price

$12.66

Market Cap

351.3M

Sector

Finance

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$0.84

Market Cap

308.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JRI
HUMA
Founded
2012
2004
Country
United States
United States
Employees
N/A
184
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
351.3M
308.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JRI
HUMA
Price
$12.66
$0.84
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$6.19
AVG Volume (30 Days)
141.4K
8.7M
Earning Date
01-01-0001
05-15-2026
Dividend Yield
9.38%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$444.16
Revenue Next Year
N/A
$248.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.67
$0.55
52 Week High
$14.37
$2.84

Technical Indicators

Market Signals
Indicator
JRI
HUMA
Relative Strength Index (RSI) 46.18 35.21
Support Level $12.42 $0.60
Resistance Level $13.20 $1.28
Average True Range (ATR) 0.23 0.11
MACD -0.01 -0.07
Stochastic Oscillator 47.41 0.07

Price Performance

Historical Comparison
JRI
HUMA

About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest

Nuveen Real Asset Income and Growth Fund is a closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: